Stoke TherapeuticsSTOK +1.01%45 Return-on-Tangible-Asset is -46.42% as of Mar. 2026. GuruFocus rates STOK with a GF Score™ of 45/100 and a GF Value™ of $10.13 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,412 Biotechnology companies, Stoke Therapeutics ranks worse than 54.32% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Stoke Therapeutics's annualizedNet Income for the quarter that ended in Mar. 2026 was $-200.01 Mil. Stoke Therapeutics's average total tangible assets for the quarter that ended in Mar. 2026 was $430.86 Mil. Therefore, Stoke Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -46.42%.
The historical rank and industry rank for Stoke Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
STOK'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -227.88 Med: -31.97 Max: -2
Current: -42.16
During the past 9 years, Stoke Therapeutics's highest Return-on-Tangible-Asset was -2.00%. The lowest was -227.88%. And the median was -31.97%.
STOK's Return-on-Tangible-Asset is ranked worse than 54.32% of 1412
companies
in the Biotechnology industry
Industry Median: -35.475
vs STOK: -42.16
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Stoke Therapeutics Return-on-Tangible-Asset Related Terms
Stoke Therapeutics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Stoke Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STOK vs VRDN, ZLAB, NUVB: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Stoke Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -46.42% mean?
Stoke Therapeutics (STOK) has a Return-on-Tangible-Asset of -46.42% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Stoke Therapeutics and its competitors. According to the industry distribution chart, Stoke Therapeutics ranks #767 out of 1412 companies in the Biotechnology industry, placing it in the top 54.3%.
Is Stoke Therapeutics' Return-on-Tangible-Asset too high?
Stoke Therapeutics' current Return-on-Tangible-Asset is -46.42%. Based on the distribution chart, Stoke Therapeutics ranks #767 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' Return-on-Tangible-Asset compare to VRDN and ZLAB?
According to the Biotechnology industry distribution chart, Stoke Therapeutics ranks #767 out of 1412 companies for Return-on-Tangible-Asset. This places Stoke Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Stoke Therapeutics and its competitors. Stoke Therapeutics's current Return-on-Tangible-Asset is -46.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.13, compared to a current price of $32.98 — trading 225.6% above its estimated fair value. The current Return-on-Tangible-Asset is -46.42%. Stoke Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current Return-on-Tangible-Asset is -46.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (STOK) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of $32.98 is trading 225.6% above its estimated GF Value™ of $10.13.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for STOK:
Return-on-Tangible-Asset: -46.42%
GF Value™: $10.13 vs. price of $32.98 (225.6% above fair value)
No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score
Get the complete analysis for STOK
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STOK has been successfully added to your 
